1.39
+0.1(+7.75%)
Currency In USD
| Previous Close | 1.29 |
| Open | 1.31 |
| Day High | 1.41 |
| Day Low | 1.26 |
| 52-Week High | 43.69 |
| 52-Week Low | 1.1 |
| Volume | 129,691 |
| Average Volume | 334,944 |
| Market Cap | 3.26M |
| PE | 0.03 |
| EPS | 40.06 |
| Moving Average 50 Days | 1.49 |
| Moving Average 200 Days | 7.63 |
| Change | 0.1 |
If you invested $1000 in GRI Bio, Inc. (GRI) since IPO date, it would be worth $0 as of July 01, 2025 at a share price of $1.39. Whereas If you bought $1000 worth of GRI Bio, Inc. (GRI) shares 3 years ago, it would be worth $0.05 as of July 01, 2025 at a share price of $1.39.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire Inc.
6 hours ago
Currently available treatments for IPF are limited to only two approved drugs that come with significant side-effects, limited patient compliance and no impact on survival 2- and 6-week interim safety results demonstrated GRI-0621 to be safe and well
GRI Bio’s GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
GlobeNewswire Inc.
Jun 26, 2025 12:00 PM GMT
The Independent Data Monitoring Committee (“IDMC”) has recommended to continue the study as planned as there are no safety concerns demonstrated in the data reviewed Interim results to date demonstrate GRI-0621 to be safe and well-tolerated in the fi
GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results
GlobeNewswire Inc.
May 22, 2025 12:00 PM GMT
Data presented at the 2025 American Thoracic Society (ATS) International Conference Pre-clinical and interim clinical results underscore GRI-0621’s potential to have both anti-inflammatory and anti-fibrotic effects in pulmonary fibrosis Results from